News
Medovate’s game-changing anaesthesia device SAFIRA® receives European CE regulatory approval
16th September, 2020
Medovate – a pioneering medical device development company specialising in anaesthesia, airway management, critical care, and surgery – announced it has received CE Mark Approval for its game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia).
News
Medovate announces distribution agreement with LTR Medical for sales of SAFIRA® in Australia and New Zealand
9th September, 2020
Medovate, HEE’s medical device development partner, has concluded a distribution agreement with Brisbane-based, LTR Medical which will provide exclusivity for SAFIRA® (SAFer Injection for Regional Anaesthesia) in Australia and New Zealand.
News
Ablatus awarded over £1m Innovate UK grant for next-generation tumour ablation treatment
26th August, 2020
Cambridge-based Ablatus Therapeutics Limited has been awarded £1.4m by the UK government’s Innovate UK to develop its next-generation, minimally-invasive treatment for soft tissue tumours. The award will fund a 2-year project to develop the prototype device into a final version for use in patients for the first time.
